162 related articles for article (PubMed ID: 35547260)
1. Identification of Neoantigens and Construction of Immune Subtypes in Prostate Adenocarcinoma.
Gao Y; Wang G; Chen Y; Zhang M; Gao W; Shang Z; Niu Y
Front Genet; 2022; 13():886983. PubMed ID: 35547260
[No Abstract] [Full Text] [Related]
2. Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development.
Huang X; Zhang G; Tang T; Liang T
Mol Cancer; 2021 Mar; 20(1):44. PubMed ID: 33648511
[TBL] [Abstract][Full Text] [Related]
3. Tumor-antigens and immune landscapes identification for prostate adenocarcinoma mRNA vaccine.
Zheng X; Xu H; Yi X; Zhang T; Wei Q; Li H; Ai J
Mol Cancer; 2021 Dec; 20(1):160. PubMed ID: 34872584
[TBL] [Abstract][Full Text] [Related]
4. Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development.
Huang X; Tang T; Zhang G; Liang T
Mol Cancer; 2021 Mar; 20(1):50. PubMed ID: 33685460
[TBL] [Abstract][Full Text] [Related]
5. Bioinformatics analyses for the identification of tumor antigens and immune subtypes of gastric adenocarcinoma.
Wei S; Sun Q; Chen J; Li X; Hu Z
Front Genet; 2022; 13():1068112. PubMed ID: 36579327
[No Abstract] [Full Text] [Related]
6. Identification of tumor antigens and immune subtypes of acute myeloid leukemia for mRNA vaccine development.
Wang F
Clin Transl Oncol; 2023 Jul; 25(7):2204-2223. PubMed ID: 36781600
[TBL] [Abstract][Full Text] [Related]
7. Identification of Tumor Antigens and Immune Subtypes of Glioblastoma for mRNA Vaccine Development.
Lin H; Wang K; Xiong Y; Zhou L; Yang Y; Chen S; Xu P; Zhou Y; Mao R; Lv G; Wang P; Zhou D
Front Immunol; 2022; 13():773264. PubMed ID: 35185876
[TBL] [Abstract][Full Text] [Related]
8. Recognition of Tumor-Associated Antigens and Immune Subtypes in Glioma for mRNA Vaccine Development.
Ma S; Ba Y; Ji H; Wang F; Du J; Hu S
Front Immunol; 2021; 12():738435. PubMed ID: 34603319
[TBL] [Abstract][Full Text] [Related]
9. Identification of tumor-specific neoantigens and immune clusters of hepatocellular carcinoma for mRNA vaccine development.
Li YF; Hou QQ; Zhao S; Chen X; Tang M; Li L
J Cancer Res Clin Oncol; 2023 Feb; 149(2):623-637. PubMed ID: 36239794
[TBL] [Abstract][Full Text] [Related]
10. Dissecting Tumor Antigens and Immune Subtypes of Glioma to Develop mRNA Vaccine.
Zhong H; Liu S; Cao F; Zhao Y; Zhou J; Tang F; Peng Z; Li Y; Xu S; Wang C; Yang G; Li ZQ
Front Immunol; 2021; 12():709986. PubMed ID: 34512630
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive Analyses of Immune Subtypes of Stomach Adenocarcinoma for mRNA Vaccination.
You W; Ouyang J; Cai Z; Chen Y; Wu X
Front Immunol; 2022; 13():827506. PubMed ID: 35874675
[TBL] [Abstract][Full Text] [Related]
12. Identification of Potential Antigens for Developing mRNA Vaccine for Immunologically Cold Mesothelioma.
Zhang S; Li S; Wei Y; Xiong Y; Liu Q; Hu Z; Zeng Z; Tang F; Ouyang Y
Front Cell Dev Biol; 2022; 10():879278. PubMed ID: 35846349
[TBL] [Abstract][Full Text] [Related]
13. Tumor antigens and immune subtypes of glioblastoma: the fundamentals of mRNA vaccine and individualized immunotherapy development.
Wu C; Qin C; Long W; Wang X; Xiao K; Liu Q
J Big Data; 2022; 9(1):92. PubMed ID: 35855914
[TBL] [Abstract][Full Text] [Related]
14. Identification of Tumor Antigens and Immune Landscape in Glioblastoma for mRNA Vaccine Development.
Ye L; Wang L; Yang J; Hu P; Zhang C; Tong S; Liu Z; Tian D
Front Genet; 2021; 12():701065. PubMed ID: 34527020
[No Abstract] [Full Text] [Related]
15. Identification of Novel Tumor Pyroptosis-Related Antigens and Pyroptosis Subtypes for Developing mRNA Vaccines in Pancreatic Adenocarcinoma.
Lin Q; Liang L; Wang Q; Wang X; You Y; Rong Y; Zhou Y; Guo X
Biomedicines; 2024 Mar; 12(4):. PubMed ID: 38672082
[TBL] [Abstract][Full Text] [Related]
16. Immune infiltration phenotypes of prostate adenocarcinoma and their clinical implications.
Ma Z; Cheng X; Yue T; Shangguan X; Xin Z; Zhang W; Pan J; Wang Q; Xue W
Cancer Med; 2021 Aug; 10(15):5358-5374. PubMed ID: 34128342
[TBL] [Abstract][Full Text] [Related]
17. Identification of Novel Tumor Antigens and the Immune Landscapes of Bladder Cancer Patients for mRNA Vaccine Development.
Wang G; Gao Y; Chen Y; Wang K; Zhang S; Li G
Front Oncol; 2022; 12():921711. PubMed ID: 35814377
[TBL] [Abstract][Full Text] [Related]
18. Identification of tumor antigens and immune subtypes of hepatocellular carcinoma for mRNA vaccine development.
Lu TL; Li CL; Gong YQ; Hou FT; Chen CW
World J Gastrointest Oncol; 2023 Oct; 15(10):1717-1738. PubMed ID: 37969406
[TBL] [Abstract][Full Text] [Related]
19. Identification of neoantigens and immunological subtypes in clear cell renal cell carcinoma for mRNA vaccine development and patient selection.
Zhu D; Yang J; Zhang M; Han Z; Shao M; Fan Q; Ma Y; Xie D; Xiao W
Aging (Albany NY); 2023 Jun; 15(11):5190-5214. PubMed ID: 37315301
[TBL] [Abstract][Full Text] [Related]
20. Development of a novel five-gene immune-related risk model for the prognosis evaluation of prostate adenocarcinoma patients.
Fei H; Chen X
Am J Cancer Res; 2022; 12(5):2337-2349. PubMed ID: 35693084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]